La chaîne d'options affiche les données clés des options sur actions de Genmab à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Genmab..

Genmab (NASDAQ:GMAB) Stock, Chaîne d'Options

GENMAB A/S -SP ADR

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS

Better Choice Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#NYSE">BTTR</a>) ("Better Choice" or the "Company"), a pet health and wellness company, is pleased to announce that SRx Health Solutions, Inc. ("SRx Health")&nbsp;has signed a definitive agreement to convert $4 million in debt to equity, improving SRx Health working capital position and future cash flow. This strategic investment was made by a strategic distribution partner to invest in the Company's mission to deliver innovative, sustainable, and integrated healthcare solutions to patients in North America.
This investment is pending the closing of the merger between SRx Health Solutions and Better Choice Company, which is scheduled for late-April. Upon closing, the combined companies will emerge as a leading global health and wellness company, delivering enhanced products and solutions for pets, people, and families.

News

Financing

BTTR

Better Choice Company Announces SRx Health Solutions To Convert $4M In Debt To Equity, Strengthening Working Capital And Cash Flow Ahead Of Merger

Baird analyst David Koning maintains Paymentus Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) with a Outperform and lowers the price target from $36 to $30.

Price Target

Analyst Ratings

Baird Maintains Outperform on Paymentus Holdings, Lowers Price Target to $30

Baird analyst David Koning maintains Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) with a Neutral and raises the price target from $80 to $82.

Baird Maintains Neutral on Fidelity National Info, Raises Price Target to $82

<a href="https://www.theinformation.com/articles/meta-nears-release-new-ai-model-performance-hiccups">https://www.theinformation.com/articles/meta-nears-release-new-ai-model-performance-hiccups</a>
&nbsp;

'Meta Nears Release Of New AI Model After Performance Hiccups' - The Information

Scrolling through social media lately feels like stepping into a Studio Ghibli film. Thanks to <a href="https://www.benzinga.com/startups/24/10/41312615/investors-pour-billions-into-openai-whats-driving-this-unprecedented-surge-in-funding">OpenAI</a>&#8216;s latest ChatGPT update, people are transforming their selfies into whimsical, hand-drawn portraits inspired by the famed Japanese animation studio.&nbsp;
The trend, dubbed &#8220;Ghiblification,&#8221; has taken over timelines as users share AI-generated versions of themselves, their pets, and even popular internet memes.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/startengine-own">The $1.3 billion startup investment boom: How this company's explosive growth is opening doors for everyday investors with a new $500 minimum</a></li>
</ul>
<h2 class="wp-block-heading">Ghiblification takes over social media</h2>
Social media feeds are overflowing with these AI-generated images. From X to Instagram, people are reimagining themselves in the dreamy, soft-colored worlds that define Ghibli&#8217;s visual style.&nbsp;
Germany-based entrepreneur and founder of FeatherFlow, Janu Lingeswaran, shared his excitement after using the tool to turn a photo of his 3-year-old ragdoll cat, Mali, into a Ghibli-esque character. &#8220;I really fell in love with the result. We&#8217;re thinking of printing it out and hanging it on the wall,&#8221; he said, according to <a href="https://apnews.com/article/studio-ghibli-chatgpt-images-hayao-miyazaki-openai-0f4cb487ec3042dd5b43ad47879b91f4">The Associated Press</a>.
Even OpenAI CEO Sam Altman got in on the trend, updating his profile picture to a Ghibli-style portrait.<a href="https://x.com/sama/status/1904921537884676398"> His reaction on X</a>? A mix of humor and irony:
&nbsp;&gt;be me&nbsp;
&gt; Grind for a decade trying to help make superintelligence to cure cancer or whatever&nbsp;
&gt; Mostly no one cares for first 7.5 years, then for 2.5 years, everyone hates you for everything&nbsp;
&gt; wake up one day to hundreds of messages: &#8220;Look, I made you into a Twink Ghibli style haha&#8221;
— Sam Altman (@sama) March 26, 2025
Trending: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.
While the trend has been fun for many, it&#8217;s also sparked a storm of debate over copyright and artistic integrity.
Not everyone is thrilled about AI recreating iconic artistic styles. Mumbai-based artist and founder of Studio Joog, Jugal Chudasama, told<a href="https://www.theweek.in/news/sci-tech/2025/03/29/ghibli-trend-generated-your-ghibli-style-ai-image-why-it-is-ethically-wrong-and-may-amount-to-stealing-art-plagiarism.html?"> The Week</a>, &#8220;These AI models are trained without the intellectual property owner&#8217;s consent.&#8221; Critics argue that mimicking a studio&#8217;s visual language without permission or compensation raises serious ethical concerns.&nbsp;
Studio Ghibli co-founder Hayao Miyazaki has long opposed AI art. In the 2016 NHK documentary "Hayao Miyazaki: The One Who Never Ends," Miyazaki <a href="https://www.youtube.com/watch?v=ngZ0K3lWKRc">called</a> AI art &#8220;an insult to life itself.&#8221;
Legal experts say AI-generated images exist in a gray area of copyright law. <a href="https://itsartlaw.org/2025/03/04/recent-developments-in-ai-art-copyright-copyright-office-report-new-registrations/">The Center of Art Law</a> says AI-generated outputs lack meaningful human creative input, and the necessary authorship required for protection under the Copyright Act.
See Also: This platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"> and you can be a part of it for $0.18 per share</a>
While specific works are protected, broader artistic styles aren&#8217;t—making it challenging for companies like Ghibli to take legal action. This gap leaves independent artists vulnerable to having their unique styles replicated without consent.
The art community remains divided. According to <a href="https://interestingengineering.com/culture/openai-creates-ghibli-style-images">Interesting Engineering</a>, artist Karla Ortiz called OpenAI&#8217;s use of Ghibli branding &#8220;an insult&#8221; and "exploitation." Others, especially in tech, argue that AI-generated art democratizes creativity by allowing people without formal training to produce visually striking work.
This isn&#8217;t the first time <a href="https://www.benzinga.com/news/25/02/43903135/ais-19-9-trillion-impact-could-create-the-first-trillionaire-but-mark-cuban-says-it-wont-be-musk-or-bezos">AI</a>-generated content has sparked backlash. A fan-made <a href="https://www.youtube.com/watch?v=rtFRuo-HX1w">AI-generated trailer</a> for a hypothetical live-action version of the animated "Princess Mononoke" film went viral. That led to outrage from fans and animators who said it undermined the original film&#8217;s artistic vision. However, the trailer is not an official project, and there are no plans for a live-action adaptation.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Sam Altman Jokes About OpenAI's Viral AI Tool – 'I Worked 10 Years On Superintelligence, And People Just Turn Themselves Into Ghibli Characters'

Baird analyst David Koning maintains BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) with a Neutral and lowers the price target from $82 to $55.

BILL

Baird Maintains Neutral on BILL Holdings, Lowers Price Target to $55

Baird analyst David Manthey maintains MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) with a Neutral and lowers the price target from $90 to $84.

Baird Maintains Neutral on MSC Industrial Direct Co, Lowers Price Target to $84

Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSense

Biotech

Events

General

NRSN

NeuroSense Therapeutics To Present Data From PrimeC's Phase 2b Trial In ALS At Annual American Academy of Neurology Meeting

Baird analyst Robert Mason maintains Mirion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>) with a Outperform and lowers the price target from $22 to $20.

Baird Maintains Outperform on Mirion Technologies, Lowers Price Target to $20

Baird analyst Timothy Wojs maintains Acuity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) with a Neutral and lowers the price target from $310 to $295.

Baird Maintains Neutral on Acuity, Lowers Price Target to $295

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">79.01</td>
<td align="right">0.09</td>
<td align="right">0.11</td>
<td>45.0K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">83.87</td>
<td align="right">-2.87</td>
<td align="right">-3.31</td>
<td>379.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">46.19</td>
<td align="right">-1.50</td>
<td align="right">-3.15</td>
<td>1.9 million</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">185.42</td>
<td align="right">-5.61</td>
<td align="right">-2.94</td>
<td>18.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">190.00</td>
<td align="right">-5.23</td>
<td align="right">-2.68</td>
<td>137.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">80.87</td>
<td align="right">-2.21</td>
<td align="right">-2.67</td>
<td>21.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">122.62</td>
<td align="right">-3.23</td>
<td align="right">-2.57</td>
<td>32.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">90.99</td>
<td align="right">-1.54</td>
<td align="right">-1.67</td>
<td>17.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">142.00</td>
<td align="right">-1.13</td>
<td align="right">-0.79</td>
<td>27.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.55</td>
<td align="right">-0.47</td>
<td align="right">-0.58</td>
<td>138.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">40.60</td>
<td align="right">-0.22</td>
<td align="right">-0.54</td>
<td>12.3K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> the above sector movers alert assists traders in understanding macro-level trends and market variations. Traders will look for sector movers providing information on sectors that are over- or under-performing, deriving these results into investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For April 4, 2025

Baird analyst Mark Altschwager maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Outperform and lowers the price target from $450 to $370.

LULU

Baird Maintains Outperform on Lululemon Athletica, Lowers Price Target to $370

Offerings

MOBX

Mobix Labs Announces Registered Direct Offering Of 4,876,860 Shares At Purchase Price Of $0.8202/Share

Shares of beverage giant Coca-Cola Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) hit an all-time high on Thursday. The milestone could help investor Warren Buffett be well on his way to<a href="https://www.benzinga.com/general/education/25/01/42832123/warren-buffett-beats-sp-500-in-2024-how-oracle-of-omahas-returns-compare-over-past-20-years"> beating the S&amp;P 500 </a>once again in 2025.
For decades, Coca-Cola has been a staple in Buffett's Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) portfolio. Here's a look back at the firm's very first purchase and how investors would have done had they invested in Coca-Cola stock when Buffett did.
What Happened:&nbsp;Berkshire Hathaway&#8217;s portfolio includes holdings in top public companies such as&nbsp;Coca-Cola, Apple Inc, American Express&nbsp;and more. It also owns many well-known companies, including&nbsp;Dairy Queen, Duracell, GEICO&nbsp;and&nbsp;<a href="https://www.benzinga.com/general/entertainment/22/03/26224759/warren-buffett-owns-what-10-berkshire-acquisitions-you-may-have-forgotten" target="_blank" rel="noreferrer noopener">Fruit of the Loom.</a>
In 1988, Buffett and Berkshire Hathaway made a splash by buying shares of Coca-Cola. By the end of the year, Berkshire Hathaway had acquired 14,172,500 shares at an average price point of $41.81.
In an annual letter that year, Buffett, who is said to drink five cans of Coke or Cherry Coke daily, addressed the purchase of Coca-Cola shares.
"In 1988, we made major purchases of Federal Home Loan Mortgage Pfd and Coca-Cola. We expect to hold these securities for a long time," Buffett said. "In fact, when we own portions of outstanding businesses with outstanding managements, our favorite holding period is forever."
Berkshire Hathaway would continue to add to its Coca-Cola position over the following years and see its share count blossom from several stock splits.
The firm now owns 400 million Coca-Cola shares, making up around 10.9% of its portfolio. Berkshire Hathaway owns over 9% of Coca-Cola's shares.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/02/43623639/coca-cola-pops-in-q4-revenue-soars-6-ceo-hails-all-weather-strategy">Coca-Cola Pops In Q4—Revenue Soars 6%, CEO Hails &#8216;All-Weather Strategy&#8217;</a>
Investing $1,000 in Coca-Cola: Buffett&#8217;s big bet in 1988 marked one of the investor&#8217;s largest bets on a public company.
If a person had invested at the same price and time Berkshire Hathaway had purchased its shares, that investor would have been pleasantly rewarded today.
A $1,000 investment at the time could have purchased 23.92 shares of Coca-Cola. Shares of Coca-Cola split 2-for-1 in 1990, 1992, 1996 and 2012. The stock splits would have turned the $1,000 investment into 382.72 shares.
Today, the $1,000 investment would be worth $27,969.18, based on a price of $73.08 at the time of writing, and not including dividends.
The investment would be up a staggering 2,696.9% over the last 37 years.
Not every investment Buffett makes is a winner. Still, the legendary investor proves that many of Berkshire Hathaway&#8217;s top holdings enjoy a nice return on investment when held for many years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/12/42734838/warren-buffetts-chilling-warning-to-employees-lose-a-shred-of-reputation-for-the-firm-and-i-will-be-ruthless">Warren Buffett&#8217;s Chilling Warning To Employees: &#8216;Lose A Shred Of Reputation For The Firm And I Will Be Ruthless&#8217;</a></li>
</ul>
This article was previously published by Benzinga and has been updated.

If You Invested $1,000 In Coca-Cola Stock When Warren Buffett Did, Here's How Much You'd Have Today

Dan Morehead, Founder and Managing Partner of Pantera Capital, believes crypto markets have not yet fully absorbed a wave of major political and regulatory developments <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44631522/bitcoin-as-trump-tariff-safe-haven-not-yet-but-might-decouple-over-time-expert-says">that favor the industry.</a> 
What Happened: In an X <a href="https://x.com/dan_pantera/status/1907449391004123355?s=46">post</a> on Friday, Morehead pointed to the muted market reaction to what he described as an exceptionally bullish environment for digital assets.
"If a few days before the U.S. Presidential election – with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) at $69,000 – a sorcerer showed you a crystal ball", revealing pro-crypto outcomes across the executive and legislative branches, "you'd bet bitcoin would be up way more than 24%," Morehead wrote.
He cited a number of developments since the November election: a <a href="https://www.benzinga.com/25/03/44478350/donald-trumps-bitcoin-bust-why-did-btc-perform-better-during-joe-bidens-first-two-months">pro-crypto president entering office</a>, a Republican-controlled Congress, the removal of dozens of <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44499057/sec-crypto-task-force-schedules-four-more-roundtables-on-regulation">anti-crypto lawmakers</a> and several executive orders establishing a U.S. <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44628685/bitcoin-is-a-realistic-global-reserve-asset-experts-say">strategic reserve</a> of Bitcoin and other digital assets.
Additionally, the White House has dropped many of the <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44398151/ripple-ceo-announces-victory-as-sec-drops-appeal-in-xrp-lawsuit">SEC's enforcement actions</a> targeting the blockchain sector and is actively engaging the industry through a dedicated summit.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44627407/gold-overtaking-bitcoin-in-inflation-hedge-strategy-jpmorgan-says">Gold Overtaking Bitcoin In Inflation Hedge Strategy, JPMorgan Says</a>
Why It Matters: Despite this rapid shift in the policy landscape, Morehead pointed out that Bitcoin's price remains within a relatively narrow range.
"The way I think of it, the markets have barely moved relative to trend," he said, noting that the Pantera Bitcoin Fund's long-term average annual return stands at 83%, a pace that could explain much of Bitcoin's recent gains without accounting for the current political tailwinds.
"Seems to me that the crypto markets have yet to price in the very positive developments," Morehead concluded.
Pantera Capital, one of the earliest institutional investors in crypto, has historically emphasized the importance of macro conditions and regulatory clarity in driving digital asset adoption. 
Morehead's comments suggest he sees current market valuations as lagging behind the fundamental shift in Washington&#8217;s <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44628685/bitcoin-is-a-realistic-global-reserve-asset-experts-say">stance toward the industry.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44625640/anthony-pompliano-praises-trumps-tariffs-as-catalyst-for-crypto-innovation">Anthony Pompliano Praises Trump&#8217;s Tariffs As Catalyst For Crypto Innovation</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Has Yet To Price In 'Very Positive Developments,' Pantera Capital's Dan Morehead Says

Baird analyst Craig Kennison maintains Harley-Davidson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>) with a Neutral and lowers the price target from $32 to $26.

Baird Maintains Neutral on Harley-Davidson, Lowers Price Target to $26

Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq&#xAE;)
The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination with atezolizumab in patients with platinum-resistant ovarian cancer (PROC), without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level
Stable disease (SD) at four months post-initiation of dosing was seen in 5 of 15 evaluable patients (33%), with 4 continuing beyond 6 months
One patient with PROC who was dosed at the MTD had a partial response (PR) by RECIST criteria (44% decrease from baseline) and &gt;2x decrease in the CA 125 biomarker

SONN

Sonnet BioTherapeutics Holdings Announces Safety Results Of Son-1010 At Highest Dose Combined With Atezolizumab In Phase 1b/2a Clinical Trial In Adult Patients With Advanced Solid Tumors Or Platinum-resistant Ovarian Cancer

Baird analyst Craig Kennison maintains Fox Factory Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXF#NASDAQ">FOXF</a>) with a Neutral and lowers the price target from $32 to $25.

FOXF

Baird Maintains Neutral on Fox Factory Holding, Lowers Price Target to $25

Baird analyst Colin Sebastian maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Neutral and lowers the price target from $250 to $200.

CVNA

Baird Maintains Neutral on Carvana, Lowers Price Target to $200

XChange TEC.INC Acquires A Hong Kong Insurance Brokerage Firm, Terms Not Disclosed

Press Releases

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab Publishes 2024 Annual Report

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Comments

Genmab

Genmab (GMAB) Options

Genmab (NASDAQ:GMAB) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL